Euroasian journal of hepato-gastroenterology

Register      Login

SEARCH WITHIN CONTENT

FIND ARTICLE

Volume / Issue

Online First

Archive
Volume  14 (2024)
Volume  13 (2023)
Volume  12 (2022)
Volume  11 (2021)
Volume  10 (2020)
Volume  9 (2019)
Volume  8 (2018)
Volume  7 (2017)
Volume  6 (2016)
Volume  5 (2015)
Volume  4 (2014)
Volume  3 (2013)
Volume  2 (2012)
Volume  1 (2011)
Related articles

VOLUME 13 , ISSUE 1 ( January-June, 2023 ) > List of Articles

CASE REPORT

Acute Hepatitis in an Immunosuppressed Patient: A Dilemma

Tarana Gupta

Keywords : Acute hepatitis, Carcinoma buccal mucosa, Cisplatin, Occult hepatitis B, Occult hepatitis C

Citation Information : Gupta T. Acute Hepatitis in an Immunosuppressed Patient: A Dilemma. Euroasian J Hepatogastroenterol 2023; 13 (1):26-27.

DOI: 10.5005/jp-journals-10018-1368

License: CC BY-NC 4.0

Published Online: 03-08-2023

Copyright Statement:  Copyright © 2023; The Author(s).


Abstract

Acute hepatitis in patients on chemotherapy has always been challenging. Demystifying the truth becomes essential to continue chemotherapy. We present a case of carcinoma buccal mucosa who developed acute hepatitis following a single dose of cisplatin and radiotherapy. In the background of a history of chronic alcoholism, and alcohol abstinence of more than 3 months, acute alcoholic hepatitis was unlikely. Though he had occult hepatitis B with HBsAg negative and positive IgG anti-HBc antibody status, however, with undetectable HBV DNA PCR quantitative, hepatitis B was unlikely to be the cause of acute hepatitis. With all viral markers including atypical viruses and autoimmune work-up being negative, it was a real-time challenge to find the exact cause.

HTML PDF Share
  1. Ali NK, Mohamed RR, Saleh BE, et al. Occult hepatitis C virus infection among haemodialysis patients. Arab J Gastroenterol 2018;19(3): 101–105. DOI: 10.1016/j.ajg.2018.09.001.
  2. Pawlotsky JM. Use and interpretation of virological tests for hepatitis C. Hepatology 2002;36(5 Suppl 1):S65–S73. DOI: 10.1053/jhep.2002.36815.
  3. Lefrère JJ, Guiramand S, Lefrère F, et al. Full or partial seroreversion in patients infected by hepatitis C virus. J Infect Dis 1997;175(2):316–322. DOI: 10.1093/infdis/175.2.316.
  4. Takaki A, Wiese M, Maertens G, et al. Cellular immune responses persist and humoral responses decrease two decades after recovery from a single-source outbreak of hepatitis C. Nat Med 2000;6(5): 578–582. DOI: 10.1038/75063.
  5. Cersosimo RJ. Hepatotoxicity associated with cisplatin chemotherapy. Ann Pharmacother 1993;27(4):438–441. DOI: 10.1177/106002809302700408.
  6. Gabrovska M, Geurs F, Ponette S, et al. Weekly cisplatin may reverse liver dysfunction and jaundice caused by diffuse liver metastases of solid tumors. Hepat Med 2009;1:9–12. DOI: 10.2147/hmer.s7574.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.